Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.
You may also be interested in...
Forest’s Namenda To Get Label Update After Pediatric Program Failure
But Alzheimer’s indication for Namenda and extended-release version will get six months of pediatric exclusivity with a pending NDA for a combo-treatment eligible for the same perks.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.